Timing is everything, especially when it comes to investing in stocks like Monopar Therapeutics. As we step into November, investors are keenly watching MNPR to determine whether it's on the brink of a comeback or headed for more turbulence. This biotechnology company, with its fiscal year ending in December, has seen its stock price fluctuate significantly, hitting a 52-week high of $38.50 and a low of $1.37. Currently, the stock's 200-day moving average sits at $3.70, suggesting a potential pivot point for traders. Despite the challenges, including an operating income loss of 8.8 million, analysts remain optimistic, with a strong buy consensus and a highest estimated target price of $9.44. As the market evaluates these signals, the question remains: will Monopar Therapeutics find its footing or continue its downward trend? Biotechnology is an exciting field, and Monopar Therapeutics is a company worth watching in this sector. Despite recent price movements that diverged from broader market trends, there are reasons to remain optimistic about a potential recovery. While some fundamental indicators suggest challenges that could lead to prolonged losses for retail investors, the stock is currently seeing higher-than-average trading activity. This increased interest might signal investor confidence or anticipation of positive developments.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of Monopar Therapeutics. In general, sophisticated investors focus on analyzing Monopar Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Monopar Therapeutics's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of Monopar Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Monopar Therapeutics, many experienced traders also check how macroeconomic factors affect Monopar Therapeutics price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
How important is Monopar Therapeutics's Liquidity
Monopar Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance Monopar Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Monopar Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Monopar Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Monopar Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Monopar Therapeutics's total debt and its cash.
Monopar Therapeutics Gross Profit
Monopar Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Monopar Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Monopar Therapeutics Gross Profit growth over the last 10 years. Please check Monopar Therapeutics'
gross profit and other
fundamental indicators for more details.
Closer look at Monopar Therapeutics Downside Variance
Monopar Therapeutics has current Downside Variance of 134.65. Downside Variance (or DV) is measured by target semi-variance and is termed downside volatility. It is expressed in percentages and therefore allows for rankings in the same way as variance. One way to view downside volatility is the annualized variance of returns below the target.
Downside Variance is the probability-weighted squared below-target returns.
The squaring of the below-target returns has the effect of penalizing failures at an exponential rate. This is consistent with observations made on the behavior of individual decision-making under.
Downside Variance | = | SUM(RET DEV)2N(ER) |
| = | 134.65 |
| SUM | = | Summation notation |
| RET DEV | = | Actual returns deviation over selected period |
| N(ER) | = | Number of points with returns less than expected return for the period |
Let's now compare Monopar Therapeutics Downside Variance to its closest peers:
| MNPR | 134.65 |
| ANEB | 66.74 |
| ACRV | 14.44 |
| PMVP | 7.03 |
| MOLN | 38.68 |
Buy low, sell high is a mantra that resonates with every investor, and Monopar Therapeutics (MNPR) might just be a stock to watch closely this November. With a 52-week low of 1.37 and a high of 38.50, the stock has shown significant volatility, which could present opportunities for savvy traders. The company's strong current ratio of 7.61X suggests it has ample liquidity to cover short-term obligations, potentially positioning it for a rebound. However, with a net income loss of 8.4 million, investors should weigh the risks carefully. As MNPR trades on the NASDAQ, its beta of 1.26 indicates a higher volatility compared to the market, making it crucial for investors to stay informed and ready to act..
Are you still wavering about Monopar Therapeutics?
If you're undecided about Monopar Therapeutics, here's something to consider: the stock's recent Jensen's Alpha is an impressive 9.62. This suggests Monopar is delivering returns beyond what its risk profile would typically predict, indicating strong performance. Such a robust alpha can be attractive for investors looking for growth and a history of beating market expectations. However, it's important to note that Monopar's stock shows significant volatility. Understanding these fluctuations can help investors make informed decisions about when to buy or sell.
High volatility, especially during market downturns, can affect Monopar's stock price and may lead investors to adjust their portfolios. This often involves diversifying into other assets as prices drop, aiming to manage risk and stabilize returns.As we look ahead to November, Monopar Therapeutics presents an intriguing opportunity for investors willing to navigate the biotech sector's inherent volatility. With an analyst overall consensus of "Strong Buy" and a highest estimated target price of $9.44, there is potential for significant upside. However, it's crucial to weigh this against the possible downside price of $0.17, which underscores the risks involved. For those with a higher risk tolerance, Monopar's innovative pipeline and strategic developments could offer a rewarding investment, but it's essential to stay informed and agile as new information emerges..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Monopar Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com